glp-1 foods What to Eat on a Diet, According to a Dietitian All about GLP-1! Whether you're

This ensures glp1 medication is used safely and effectively

Patients with PWS are characterized by neonatal hypotonia, hyperphagia, developmental and cognitive delay, behavioral problems, dysmorphic features, and failure to thrive [3]

Novo Nordisk has cut its full-year forecast three times in 2025 as GLP-1 growth rates decelerated sharply

In contrast, patients with diabetes may be more accustomed to long-term medication routines, making adherence more stable

However, Novo Nordisk is expected to emerge as the leading company, having a large portfolio of GLP1 drugs, and is expected to capture 55 per cent of the market share in 2029.